Interpace Biosciences to restate 2023 and quarterly 2023/2024 financials due to accrued royalty errors

INTERPACE BIOSCIENCES, INC.

Accrued royalties overstated by $5.3M to $7.1M across 2023 and 2024 quarterly balance sheets.
Restatement expected to reduce liabilities and increase net income; revenues and cash flows unchanged.
Non-reliance on financial statements for FY2023, Q1-Q3 2023 and Q1-Q3 2024.
Management will report a material weakness in internal controls over accrued royalty assessment.
Cumulative impact from 2015-2022 is $4.8M aggregate; no restatement for periods before 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.